

1 **Antibody Responses In Non-Severe SARS-CoV-2 Infections Are Driven By CD4+ T cells**  
2 **and Age.**

3  
4 Amelie E. Murrell<sup>1,12</sup>; Ewono Eyoh<sup>1,12</sup>; Jeffrey G. Shaffer<sup>2</sup>; Monika L. Dietrich<sup>3,4</sup>; Ivy V. Trinh<sup>1</sup>;  
5 Thomas J. Yockachonis<sup>6</sup>; Shuangyi Bai<sup>6</sup>; Crystal Y. Zheng<sup>7</sup>; Celia V. Mayne<sup>4</sup>; Sofia E. Cabrera<sup>3</sup>;  
6 Anyssa Aviles-Amaro<sup>1</sup>; Addison E. Stone<sup>1</sup>; Saraswatie Rambaran<sup>1</sup>; Sruti Chandra<sup>3</sup>; Debra H.  
7 Elliott<sup>3</sup>; Ashley R. Smira<sup>3</sup>; Sara N. Harris<sup>3</sup>; Katharine E. Olson<sup>3</sup>; Samantha J. Bilton<sup>1</sup>; Medea J.  
8 Gabriel<sup>3</sup>; Nicole D. Falgout<sup>3</sup>; Emily J. Engel<sup>3</sup>; Alisha D. Prystowsky<sup>3</sup>; Bo Ning<sup>8,9</sup>; Tony Hu<sup>8,9</sup>; Jay  
9 K. Kolls<sup>3,10</sup>; Samuel J. Landry<sup>9</sup>; Stacy S. Drury<sup>3,4,5</sup>; John S. Schieffelin<sup>3,4</sup>; Kevin J. Zvezdaryk<sup>1,11</sup>;  
10 James E. Robinson<sup>3,4</sup>; Bronwyn M. Gunn<sup>6,13</sup>; Elizabeth B. Norton<sup>1,11,13\*</sup>

11  
12 <sup>1</sup>Department of Microbiology & Immunology, Tulane University School of Medicine, New Orleans,  
13 LA

14 <sup>2</sup>Department of Biostatistics & Data Science, School of Public Health and Tropical Medicine,  
15 Tulane University, New Orleans, LA

16 <sup>3</sup>Department of Pediatrics, Tulane University School of Medicine, New Orleans LA

17 <sup>4</sup>Department of Child Psychiatry, Tulane University School of Medicine, New Orleans LA

18 <sup>5</sup>Children's Hospital New Orleans, New Orleans, LA

19 <sup>6</sup>Paul G. Allen School of Global Health, Washington State University, WA

20 <sup>7</sup>Department of Medicine, Section of Infectious Diseases, Tulane University School of Medicine,  
21 New Orleans LA

22 <sup>8</sup>Center for Cellular and Molecular Diagnostics, Tulane University School of Medicine, New  
23 Orleans, LA

24 <sup>9</sup>Department of Biochemistry and Molecular Biology, Tulane University School of Medicine, New  
25 Orleans, LA

26 <sup>10</sup>Center for Translational Research in Infection and Inflammation, Tulane University School of  
27 Medicine, New Orleans, LA

28 <sup>11</sup>Tulane Center for Aging, Tulane University School of Medicine, New Orleans, LA

29 <sup>12</sup>These authors contributed equally to this work

30 <sup>13</sup>These authors contributed equally to this work

31  
32 \* Correspondence: [enorton@tulane.edu](mailto:enorton@tulane.edu)

33  
34

35 **SUMMARY**

36 SARS-CoV-2 infection causes a spectrum of clinical outcomes and diverse memory responses.  
37 Population studies indicate that viral neutralizing antibody responses are protective, but do not  
38 always develop post-infection. Other antiviral antibody effector functions, T-cell responses, or  
39 immunity to seasonal coronaviruses (OC43, 229E) have been implicated but not defined in all  
40 ages. Here, we identify that children and adult subjects generate polyfunctional antibodies to the  
41 spike protein after asymptomatic infection or mild disease, with some subjects developing  
42 cellular responses without seroconversion. Diversity in immunity was explained by two clusters  
43 distinguished by CD4+ T-cell cytokines, age, and antibodies to seasonal coronaviruses. Post-  
44 vaccination neutralizing responses were predicted by specific post-infection immune measures,  
45 including IL-2, spike-IgA, OC43-IgG1, 229E-IgM. We confirm a key role for CD4+ T cell  
46 cytokines in functionality of anti-spike antibodies, and show that antibody diversity is impacted  
47 by age, Th/Th2 cytokine biases, and antibody isotypes to SARS-CoV-2 and seasonal  
48 coronaviruses.

## 49 INTRODUCTION

50 Since the start of the coronavirus disease pandemic in 2019 (COVID-19), a central question is  
51 what characterizes protective immune responses to the SARS-CoV-2 virus. The risk of SARS-  
52 CoV-2 reinfection is estimated as 0–19.5% for at least 10 months following primary infection,  
53 indicating that some level of protective immunity develops after infection [1]. Human [2-5] and  
54 animal studies [6, 7] have shown that B-cells, antibodies, CD4+ and CD8+ T-cells play essential  
55 roles in protection and memory responses. The quality and quantity of these responses are likely  
56 key to long-term protective immunity, yet the underlying mechanisms driving these immune  
57 responses are still unclear.

58 Age is a major driver of disease outcomes and significantly impacts the severity and development  
59 of SARS-CoV-immunity [8-14]. Children develop functional cellular and humoral immunity to  
60 infection but are more likely to be asymptomatic or exhibit mild COVID-19 than adults [8, 10, 15].  
61 Increased age, disease severity, and male sex have all been linked to the development of higher  
62 levels of viral-specific IgG and neutralizing antibodies post-infection [16-18]. Population-based  
63 studies have shown a central role for these neutralizing antibodies in infection and vaccine-  
64 mediated protection to SARS-CoV-2 viral strains [19-21]. Yet, antibody responses exhibit  
65 significant variation by subject, and specific protective antibody levels or tests have yet to be  
66 identified [22]. In addition, several studies have shown that antibodies with polyfunctional activities  
67 that neutralize viral entry and recruit innate immune effector functions, such as complement  
68 deposition, neutrophil, and monocyte phagocytosis, and Natural Killer (NK) cell activation, are  
69 inversely correlated with disease severity following infection [10, 19, 20, 23]. These reports  
70 indicate diversity in SARS-CoV-2 humoral immunity suggesting that the qualitative features of  
71 antibodies are likely just as important as titers and neutralizing responses.

72 T-cell responses also develop early post-infection and are sustained over time. CD4+ T-cell  
73 responses are typically characterized by a type 1 phenotype (Th1), with expression of IL-2, IFN $\gamma$ ,  
74 and TNF $\alpha$  that are induced early during SARS-CoV-2 infection with a prolonged contraction in  
75 patients with severe or mild disease [4, 24-28]. Higher Th1 cell responses have been reported in  
76 asymptomatic versus symptomatic patients, but the latter also express more inflammatory  
77 cytokines (IL-1 $\beta$ , IL-6, TNF $\alpha$ ) [24]. Interestingly, while T-cell responses are linked to the  
78 development of antibody responses [3], they are also detected in some people who never  
79 developed viral-specific antibodies; a phenomenon termed cellular sensitization without  
80 seroconversion [26] that has also been observed with other coronaviruses [29]. CD8+ T-cells  
81 have been linked to viral clearance [30, 31], but others have suggested this early control of viremia  
82 is from bystander CD8+ T-cells activation and innate immunity [26, 32]. Taken together, these  
83 studies indicate SARS-CoV-2-specific CD4+ and CD8+ T-cell responses following infection also  
84 vary in magnitude across individuals, but their importance is debated.

85 Thus, factors contributing to the diversity of SARS-CoV-2 immunity are poorly understood.  
86 Notably, most COVID-19 studies have focused on immunity generated following severe infection  
87 in hospitalized patients, reflecting less than 10% of infected individuals in the United States.  
88 Additional limitations of existing studies include inadequate representation of all age groups for  
89 non-severe infections and a focus on antibody effector functions or T-cell immunity, but rarely  
90 both. The objective of this study was to address these knowledge gaps by integrating a systems  
91 serology approach with T-cell and cytokine measures to generate a comprehensive evaluation of

92 post-infection immunity and longevity. To do so, we compared immune responses as a function  
93 of age (1–79 years) in a cohort of infected, non-hospitalized versus non-infected subjects  
94 spanning pre- and post-COVID-19 and vaccination periods.

95  
96  
97

## 98 **RESULTS:**

### 99 **Demographics of the Community Seroepidemiology and Immunity (CSI) cohort and** 100 **symptoms experienced across cohort subjects and households.**

101 We recruited a cohort of 91 individuals from 45 households located in Greater New Orleans,  
102 Louisiana, community from June 2020 to March 2021 (**Table 1**). Subjects self-reported with  
103 suspected or confirmed SARS-CoV-2 infection or exposure between March 2020 and December  
104 2020 before the circulation of Delta or Omicron variants. Each participant completed a survey that  
105 collected parameters of demographics, history of infection or exposure, and clinical signs and  
106 symptoms (**Table S1**). Importantly, none of the participants had been hospitalized for infection,  
107 although ten subjects reported visiting the emergency room for their illness.

108 SARS-CoV-2 infection in 67 subjects (74%) was confirmed either by a PCR test (n=42), SARS-  
109 CoV-2 spike or nucleoprotein specific IgG by ELISA and Luminex testing (54 and 32 subjects,  
110 respectively) or viral RNA detection in plasma (n=11) by a sensitive CRISPR assay [33, 34]. The  
111 remaining 24 subjects exhibited no evidence of SARS-CoV-2 infection. Blood samples were  
112 collected at a range of times post-symptom onset or days post-exposure (**Figure 1A**) (range of  
113 10–289 days; median of 99 days from subjects), and subjects exhibited a range of disease  
114 severity irrespective of household (**Figure 1B**).

115 Hierarchical clustering analysis on reported symptoms demonstrated that five major symptom  
116 clusters were observed across the cohort (**Figure 1C**), including no symptoms, and symptoms  
117 known to track with severe disease such as difficulty breathing, shortness of breath, and loss of  
118 taste/smell. To identify those demographic parameters associated with infection status, principal  
119 component analyses (PCA) were performed, where components were ordered according to their  
120 proportion of explained variability in the data. PCA identified two components that explained at  
121 least 10% of the variability in the data (**Figure 1D**). Infected and uninfected individuals were  
122 distinguished in Component 1 by positive PCR tests and variables related to reporting symptoms  
123 for SARS-CoV-2 infection. Select demographic variables further characterized individuals across  
124 Component 2, including subject age, chronic conditions (e.g., hypertension, high cholesterol), and  
125 BMI, but not sex, race, or household. These analyses demonstrate that medical co-morbidities  
126 observed in hospitalized COVID-19 patients were also relevant in this non-hospitalized cohort.

### 127 **Polyfunctional humoral immunity is induced following SARS-CoV-2 infection.**

128 Given the central role of antibodies in SARS-CoV-2 immunity, we quantitatively and qualitatively  
129 profiled SARS-CoV-2 specific humoral immunity in the cohort. Using multiplexed Luminex  
130 analyses, we measured plasma levels of different IgG subclasses (IgG1, IgG2, IgG3, IgG4), IgA  
131 (IgA1, IgA2), and IgM-specific for SARS-CoV-2 antigens (full-length spike protein, the receptor-

132 binding domain (RBD), and the nucleoprotein [N]) and seasonal coronaviruses (OC43, HKU1,  
133 229E, and NL63) spike proteins.

134 As expected, SARS-CoV-2 specific antibodies were significantly elevated in subjects with SARS-  
135 CoV-2 infection compared with uninfected individuals (**Figure 2A, Figure S1**). No significant  
136 differences were observed between infection groups with respect to the levels of antibodies  
137 against the seasonal coronaviruses. Sampling times post-infection differed across the cohort.  
138 While the time between sampling and infection did not correlate with increasing/decreasing IgG1  
139 across individuals, elevated levels of IgG4 were observed in samples collected further from  
140 infection, suggesting temporal development of virus-specific IgG4 (**Figure 2B**). A subset of  
141 subjects (n=18) returned for follow-up visits six months after visit 1 (and before any vaccination).  
142 In these subjects, spike- and N-specific IgG responses were relatively stable over time (Figure  
143 S2). However, a small but significant increase in spike-specific IgA1 was observed in the follow-  
144 up visit (**Figure S2**).

145 As both neutralizing antibodies and induction of antibody-mediated innate immune effector  
146 functions have been associated with antibody-mediated protection against SARS-CoV-2 infection  
147 [10, 20, 21], the ability of each subject's plasma to neutralize SARS-CoV-2 D614G pseudoviruses  
148 and induce innate immune effector functions against spike-coated targets (phagocytosis by  
149 monocytes (ADCP) or neutrophils (ADNP), complement deposition (ADCD), and NK cell  
150 activation (ADNKA) was determined. Plasma from most infected individuals was found to possess  
151 neutralizing activity and not be related to time from infection, yet interestingly a sizable subset of  
152 people (n=20; 29.8% of infected individuals) did not make neutralizing antibodies (**Figure 2C**).  
153 Similar results were observed for induction of innate immune effector functions (**Figure 2D**),  
154 although the profiles among individuals varied (**Figure S3A**). To determine if specific antibody  
155 subclasses or isotypes were associated with antiviral effector functions, we performed a  
156 correlation analysis between SARS-CoV-2 specific antibody levels and effector functions. Among  
157 infected individuals, spike and RBD-specific IgG1 were highly correlated with antiviral functional  
158 activity and symptom score (**Figure 2E, Figure S1B**), suggesting that IgG1 predominantly drives  
159 these antiviral functions, although it should be noted that IgG3 strongly correlated to ADCD. N-  
160 specific IgM was negatively associated with many of these effector functions including ADNKA,  
161 ADNP, ADCP, and neutralization. While IgM is often observed early in infections (prior to IgG  
162 response), IgM levels were detected that were not significantly associated with days post-infection  
163 or inversely related to virus-specific IgG. Thus, the IgM response we detected does not seem to  
164 have a temporal relationship with antibody maturation and class-switching. Network analyses of  
165 all antibody responses against SARS-CoV-2 and the seasonal coronaviruses further confirmed  
166 the association of SARS-CoV-2 spike and RBD-specific IgG1 with qualitative antibody functions  
167 but with limited associations to other isotypes and specificities (**Figure 2F**). Together, these data  
168 highlight the diversity of qualitative humoral immune responses observed among infected  
169 individuals.

170 **CD4+ and CD8+ T-cell immunity are induced following infection, and CD4+ Th1 responses**  
171 **strongly correlated with SARS-CoV-2 serum IgG and neutralization.**

172 To determine cellular immunity post-infection, we evaluated stored PBMCs from all subjects for  
173 CD4+ and CD8+ T-cell reactivity and cytokine secretion in response to SARS-CoV-2 spike

174 protein, nucleoprotein, or matrix peptide pools after *in vitro* stimulation for 24h. Activation was  
175 assessed by flow cytometry of stimulated versus non-stimulated PBMC cultures by gating for  
176 CD134-high expression on CD4+ T cells or CD69 expression on CD8+ T-cells as a modified  
177 activation-induced marker expression (AIM) (**Figure S4A,B**). As previously reported in SARS-  
178 CoV-2 infected subjects [4, 24, 26], significant CD4+ and CD8+ T cell AIM to spike protein or  
179 peptide were observed compared to non-infected subjects (**Figure 3A**). CD4+ T cell AIM  
180 responses were stable over 6 months in the individuals who returned for a follow-up visit (**Figure**  
181 **S2E-F**) and were not correlated with the day of sample collection (**Figure S4F**). Interestingly, a  
182 subset of infected subjects had detectable T-cell responses with no observable antibody  
183 responses (**Figure S3A,B**), indicating that these subjects exhibit cellular sensitization without  
184 seroconversion [26].

185 To further characterize the types of T cell responses that are induced in infected individuals, we  
186 measured cytokines indicative of specific T-helper (Th)-responses, cytotoxic T-cell responses, or  
187 chemokines in stimulated PBMC culture supernatants compared with unstimulated PBMC.  
188 Induced cytokine secretion was highly correlated among almost all restimulation antigens  
189 including spike protein, spike peptide, N peptide, or matrix peptide (**Figure S5**). As anticipated [4,  
190 24-28], Th1-biasing IL-2 and IFN $\gamma$  secretion was observed in response to spike and nucleoprotein,  
191 but not matrix viral antigens, in infected subjects. Th1 cytokine secretion did not correlate with the  
192 day of sample collection (**Figure 3C-E**, **Figure S4F**) but declined in follow-up visits of infected  
193 subjects (**Figure S2G-J**). Although TNF $\alpha$  secretion alone was not associated with infection, a 2.5-  
194 or 4-fold change in the three Th1-associated cytokines (IL-2, IFN $\gamma$ , and TNF $\alpha$ ) induced by spike  
195 protein and nucleoprotein peptides was observed in infected subjects (**Figure 3F**, **Figure S4E**,  
196 **S4G**). Restimulation with spike protein also induced Th2 and Th17 cytokines, including IL-5 and  
197 IL-17, the latter of which was highly correlated to IL-2 responses (**Figure S5**). Significant changes  
198 in parameters such as IL-4, IL-10, Granzyme B, and perforin were not observed for any stimulation  
199 condition related to infection status (**Figure S4E**).

200 As T-cell and cytokine secretion can impact the generation of antibodies and have been  
201 implicated in pre-existing immunity to seasonal coronaviruses, we correlated cellular immunity  
202 measures with SARS-CoV-2 and seasonal coronavirus IgG antibodies (**Figure 3G**). CD4+ T-cell  
203 AIM, IL-2 secretion, and Th1-associated cytokines were significantly correlated to plasma levels  
204 of SARS-CoV-2 spike, RBD, and N IgG. Spike peptide pools but not protein for AIM significantly  
205 correlated to OC43 and NL63 IgG. In contrast, symptom score was highly associated with TNF $\alpha$ ,  
206 IL-4, and IL-10, even though these cytokines individually were not different between infected and  
207 non-infected subjects, suggesting that these cytokines track with disease severity.

## 208 **Age drives immunity to SARS-CoV-2 infection.**

209 The diversity of the study cohort (**Table 1**) allowed us to evaluate the relationship between age,  
210 sex, and SARS-CoV-2 immunity. In infected subjects, higher levels of chronic conditions and  
211 SARS-CoV-2 symptom scores were associated with increasing age (**Figure 4A**) and correlated  
212 with increased levels of spike-specific IgG1, neutralizing antibodies, IL-2, CD8+ T-cell activation,  
213 and the related antiviral cytokines perforin and Granzyme B (**Figure 4B-D**). Minimal changes in  
214 seasonal coronavirus IgG were observed with age (**Figure 4B**). Sex had no significant impact on

215 these measures (**Figure 4B**); however, both sex and age were significantly related to IgM  
216 antibody levels to Spike and RBD (**Figure 4B**).

217 **Immunity in infected subjects can be separated into two groups based on Th1 or Th2**  
218 **biased immune responses and antibody isotypes (IgM/IgG1 or IgG2/IgG4).**

219 To dissect the relationship between cellular and serologic immunity with all disease parameters  
220 and demographic information, we used t-SNE and UMAP data visualizations for immune  
221 response to SARS-CoV-2 proteins or peptides. These analyses resulted in two distinct  
222 populations (e.g., t-SNE 1 and t-SNE 2) verified by k-means clustering (**Figure 5A, Figure S6A**).  
223 These populations were compared for all measures of SARS-CoV-2 immunity, demographic,  
224 infection, or other seasonal coronavirus variables (**Table S2**). Across the demographic and  
225 disease variables, older age was associated with population 1, and minor symptoms or specific  
226 symptoms (nausea, loss of taste, runny nose, nasal congestion) were associated with population  
227 2 (**Figure 5B, Figure S6B,D**). Sex, co-morbidities, infection status, or time from infection was not  
228 associated with either population. With regard to immune measures, population 1 was defined by  
229 typical SARS-CoV-2 immunity, including IL-2 secretion to spike, CD4+ AIM, antiviral antibody  
230 functions (ADCP, ADNP), and elevated levels of IgM to SARS-CoV-2 spike or seasonal  
231 coronaviruses (e.g., HKU1, **Figure 5C**). Neutralization was not directly associated with either  
232 cluster but correlated strongly with Th1-responses and IL-2 in population 1 (**Figure 5D, Figure**  
233 **S6E**). Alternatively, population 2 was characterized by non-classical immune measures indicative  
234 of a Th2-biased response, including IL-4, IL-13 and IL-10 secretion to spike and peptide pools  
235 and development of higher levels of IgG2 and IgG4 to RBD (**Figure 5B, Table S2**). Neutralization  
236 in this population did not correlate to Th1 cytokines but was negatively correlated with IL-4 (**Figure**  
237 **5D, Figure S6E**). In addition, perforin and ADNK activities were higher, suggesting population 2  
238 may have higher NK or NKT cell activity. These data indicate that within this non-hospitalized  
239 cohort, SARS-CoV-2 immunity can diverge into Th1-biased immunity (observed in population 1)  
240 or Th2-biased immunity (observed in population 2), likely related to patient age. It is possible that  
241 lingering viral infection or antigen also contribute to population differences, as this showed up in  
242 both UMAP and correlation analyses. (**Figure 5E, Figure S6B**).

243 These observations were complemented with a network analysis of immune parameters in SARS-  
244 CoV-2 infected subjects, which demonstrated that neutralizing and functional antibody levels were  
245 associated with CD4+ T cell help (indicated by CD4+ AIM and induction of Th1 cytokines),  
246 whereas T cell production of IL-4 and IL-10 were negatively associated with antiviral antibody  
247 functions (**Figure 5E**). The univariate correlation analysis between these T cell parameters,  
248 neutralization, and antibody effector functions in SARS-CoV-2 infected subjects further highlights  
249 that specific CD4+ T cell responses track with development of qualitatively different antibody  
250 responses (**Figure S6F**). Prior exposure to seasonal coronaviruses may also play a role in the  
251 development of qualitatively different antibodies as IgM responses against the seasonal  
252 coronaviruses, particularly 229E, were negatively associated with IL-4 and IL-10 (**Figure 5E**),  
253 reflective of our t-SNE analyses (**Figure 5C**).

254 Together, these data suggest that the balance of Th1/Th2 CD4+ T-cell responses played a key  
255 role in developing qualitative SARS-CoV-2 antibody responses and points to a potential role for  
256 IgM, but not IgG1, responses against seasonal coronaviruses in promoting Th1 immunity.

## 257 **Post-vaccination responses are predicted by Th1 immunity.**

258 With ongoing vaccinations, it is also unclear how prior infection will shape long-term and vaccine-  
259 mediated immunity. Vaccine responses and efficacy have been tied to the development of  
260 neutralizing antibody responses [11], although there is also strong evidence for T-cell or Th1  
261 responses post-vaccination [8][35].

262 To understand how prior SARS-CoV-2 immunity resulting from infection impacted vaccine-  
263 mediated immunity, we obtained follow-up samples from a subset of infected subjects who  
264 received SARS-CoV-2 vaccine (n=32; age 16–79 years old (mean 43) and 63% female). These  
265 subjects received either the two-dose mRNA vaccines from Pfizer (n=21) or Moderna (n=11) or  
266 the single-dose J&J adenovirus vector vaccine (n=1). Blood collections spanned 2–315 days post-  
267 primary immunization, with 12 subjects having two or more samples collected (**Figure 6A**). As  
268 neutralizing antibodies have been linked to vaccine efficacy [20, 21], we determined post-  
269 vaccination neutralizing antibody titers. Comparison of neutralizing antibody levels pre- and post-  
270 vaccination demonstrated that vaccination significantly increased levels of neutralizing antibodies  
271 (**Figure 6B**). Waning immunity was evident over time post-vaccination, particularly 6 months  
272 following the second mRNA immunization (**Figure 6B-C**), as others have reported [21, 36, 37].

273  
274 To determine if post-infection immune responses could predict neutralizing antibody responses  
275 to vaccination and help validate the importance of the t-SNE and network analyses in **Figure 5**,  
276 we performed a LASSO-selected regression analysis on neutralizing antibody responses  
277 observed across all subjects and time post-vaccination, or <90 days or > 90 days post-vaccination  
278 to identify the minimal features needed to predict neutralizing antibody responses within a given  
279 time frame. LASSO-selected features were then used in a partial least squares analysis to identify  
280 the variable importance in projection (VIP) features that predicted neutralization titers. Features  
281 with VIP scores >0.8 were then used to generate a PCA to determine those features that  
282 influenced vaccine-induced neutralizing antibody titer levels (**Figure 6D-E**).

283 Across all samples where collection time points spanned 2 to 315 days post-vaccination, one of  
284 the main driving factors that predicted higher levels of neutralizing antibodies was the number of  
285 days post-vaccination the samples were collected (**Figure 6D**), with samples collected before 90  
286 days of vaccination having higher neutralizing antibodies than those collected afterwards. Post-  
287 infection immune parameters that predicted higher levels of neutralizing antibodies were CD4+ T  
288 cell production of IL-2, IL-17A, as well as the levels of IgG1 specific for RBD and neutralizing  
289 antibody titers post-infection (**Figure 6D**), suggesting that robust immune activation following  
290 infection translated to elevated immunity following vaccination. Curiously, CD8+ activation  
291 responses were negative predictors of post-vaccination neutralization responses (**Figure 6D-E**,  
292 **Figure S7**). The importance of pre-existing immunity to seasonal coronaviruses was also verified  
293 in this cohort as IgG1 OC43, IgM 229E, and IgG3 HKU1 were negative predictors of post-  
294 vaccination responses. Similar responses were observed within the samples collected within 3  
295 months of vaccination and by correlation analyses (**Figure S7A-B**).

296 For samples collected after 3 months, older age, type of vaccine received, B-cell activating factor  
297 (BAFF), and lower levels of antibodies against the seasonal coronaviruses, including IgG1 OC43,  
298 IgM 229E, and IgA1 229E tracked with higher neutralizing antibodies (**Figure 6E**, **Figure S7B**),



299 suggesting that durable vaccine-mediated immunity is also shaped by prior SARS-CoV-2 and  
300 seasonal coronavirus immunity and age.

301 Finally, a comparison of the post-vaccination neutralizing antibody titers between subjects in  
302 population 1 (Th1 biased immunity) and population 2 (Th2 biased immunity) showed a trend  
303 towards higher neutralizing antibodies in population one post-vaccination (**Figure 6F**). This finding  
304 indicates that the two observed clusters partially explain diversity in SARS-CoV-2 antigen  
305 responses post-infection or vaccination based on CD4+ T-cell responses, age, and non-IgG1  
306 antibody isotypes to SARS-CoV-2 or seasonal coronaviruses.

307

## 308 **DISCUSSION**

309 This is among the first studies to comprehensively measure serological and cellular measures,  
310 combining a systems serology approach with T-cell and cytokine analysis. Our key findings  
311 confirmed that CD4+ Th1 responses and age track with qualitative features of humoral immunity,  
312 and we demonstrated that post-infection responses shape levels of vaccine-induced neutralizing  
313 antibody titers. Importantly, this study was performed in a non-hospitalized community cohort,  
314 encompassing individuals across a range of ages who experienced typical asymptomatic or mild-  
315 moderate disease, reflective of the vast majority of SARS-CoV-2 infections. As previously  
316 reported[10], infected subjects developed anti-spike, RBD, and nucleoprotein antibodies that  
317 exhibit polyfunctionality with multiple antiviral effector functions (**Figure 2, Figure S3**).  
318 Accordingly, CD4+ and CD8+ T-cell responses to spike and peptide pools were also significantly  
319 altered between infected and non-infected subjects, including high levels of Th1 cytokine  
320 expression characterized by high levels of IL-2 and also INF $\gamma$  (**Figure 3**) as expected from  
321 previous studies [4, 24-28, 38].

322 We observed diversity in immune responses following infection in this cohort, including infected  
323 subjects that did not develop neutralizing antibody responses (**Figure 2**) and T-cell responses in  
324 the absence of seroconversion (**Figure S3**). Age but not sex correlated to many of our immune  
325 measures, BMI and to the symptom severity experienced by infected subjects (**Figure 4**). This  
326 would confirm that age is a primary driver of immunity, with reduced IgG and neutralizing  
327 antibodies observed in younger ages as expected from previous reports [39, 40]. However, other  
328 antibody functions, including complement and NK activation were unaffected. Curiously IgM and  
329 IgA levels did not correlate with post-infection duration and were not reduced over a second study  
330 visit (**Figure 2, Figure S2**), though older ages were associated with higher levels of IgM (**Figure**  
331 **4**). IgM is traditionally an early response to infection, but sustained expression has been reported  
332 in asymptomatic or symptomatic convalescent patients [17, 41]; though others have found  
333 persistent IgM levels associated with reinfection or prolonged shedding of virus [42] or observed  
334 decreases immediately following infection [38]. We were unable to assess early IgM responses  
335 following infection, as the average study visit for this cohort was 93 days post-infection (**Table1**).  
336 Taken together the results presented here suggest that age-related responses to SARS-CoV-  
337 infection are likely related to isotypes generated during infection, altering antibody effector  
338 functions. Since IgM-expressing B-cells play important roles in humoral immunity for early and  
339 late antibody responses, and antigen presentation are associated with complement deposition

340 [43, 44], it is possible that IgM levels in our cohort could be more than a temporal antibody  
341 maturation response and should be studied further.

342 The combined induction of functional cellular and humoral immunity is likely a key factor in long-  
343 term immunity. We observed a much higher correlation of antibody measures to CD4+ T-cells  
344 and cytokines than to CD8+ T-cells (**Figure 3, 5**), consistent with other reports on humoral  
345 memory [45, 46]. However, CD8+ T cell activation was also significantly detected and altered by  
346 age (**Figure 3, Figure 4**), and CD8 activation to spike peptide pools seemed to limit post-  
347 vaccination neutralization responses (**Figure 6**). This finding may reflect that specific CD8+ T-cell  
348 populations limit longevity of neutralization titers after infection, as others have suggested [47] or  
349 reflect a robust CD8+ T-cell response that is also protective [48]. Interestingly, combined analyses  
350 showed that infected subjects could be delineated into two groups based on a Th1- versus Th2-  
351 biased immunity that further tracked with differential development of neutralizing antibodies  
352 following vaccination. Importantly, individuals who developed a more Th1-biased immune  
353 response following infection, including production of Th1 cytokines from activated T-cells and  
354 development of antiviral antibodies capable of inducing both neutralization and innate immune  
355 effector function, had elevated levels of neutralizing antibodies post-vaccination (**Figures 5-6**).  
356 Antibody-dependent, complement-mediated delivery of antigen to dendritic cells has been shown  
357 to enhance production of neutralizing antibodies [43], thus in addition to having higher numbers  
358 of memory B cells, one potential hypothesis is that enhanced delivery of vaccine antigens to  
359 antigen presenting cells by existing SARS-CoV-2 specific antibodies helps drive higher  
360 neutralizing antibody levels.

361 The development of Th1-biased responses in subjects within cluster 1 tracked with overall older  
362 age, but not with symptom severity or SARS-CoV-2 infection. Intriguingly, subjects in cluster 2  
363 reported experiencing more minor symptoms (e.g., nausea, runny nose (coryza), nasal  
364 congestion, cough, and headache) or specific symptoms (e.g., loss of taste) and had elevated  
365 levels of virus-specific IgG2 and IgG4 compared with subjects in cluster 1. While virus-specific  
366 IgG1 and IgG3 were not different between the two clusters, antibody functionality and  
367 neutralization were significantly different, highlighting that antibody features beyond IgG  
368 subclasses may further drive differences in antiviral functionality between the two groups.  
369 Antibody glycosylation can further modify the induction of innate immune effector functions. While  
370 we did not evaluate antibody glycosylation in this study, several studies have found that severe  
371 SARS-CoV-2 infection in hospitalized or critically ill subjects is associated with increased antibody  
372 afucosylation, leading to increased inflammation and innate immune cell-mediated  
373 immunopathology [49-52].

374 This study also revealed an association with Th2 cytokines, including IL-4, IL-13, and IL-10, which  
375 inversely correlated to neutralization after infection but only weakly to post-vaccination  
376 neutralization (**Figure 2, Figure 6, Figure S7B**). A Th2 profile has also been implicated in severe  
377 COVID disease [31], though these patients were not in our study population. IL-10 was strongly  
378 correlated with IgA response to spike in our cohort, which was a key factor in lower post-  
379 vaccination neutralization titers and longevity >3 months (**Figure 6, Figure S7**). A similar IL-4/IL-  
380 13 cytokine profile by T-cells was associated with the development of memory IgA+ B cells and  
381 not neutralization in cases of mild or severe COVID-19 [45]. However, others have shown that  
382 IgA is dominant as an early neutralizing antibody response to SARS-CoV-2 infection in mucosal

383 tissue and blood and correlates to IgG [53, 54]. mRNA vaccination is known for boosting high  
384 levels of neutralizing serum antibodies but not mucosal IgA responses even in previously infected  
385 individuals [55]. However, these findings suggest that IgA responses play a negative role in post-  
386 vaccination neutralizing antibody magnitude and duration and may be the result of IL-10 secretion  
387 that that should be explored further. Taken together, this data indicate a key role for cellular  
388 immunity and cytokine biases in infection outcomes and post-vaccination responses.

389 Whether prior exposure to seasonal coronaviruses shapes SARS-CoV-2 specific immunity has  
390 been a key question since the beginning of the pandemic. Pre-pandemic pediatric samples have  
391 been a higher level of cross-reactive IgM to SARS-CoV-2, compared with adults who have higher  
392 levels of IgG and IgA, presumably from these seasonal coronaviruses [56]. These pre-existing  
393 antibodies, particularly to OC43, are increased following infection but not vaccination [57-59],  
394 OC43 antibodies have been linked to antibody development post-infection and COVID-19 survival  
395 in hospitalized patients [58] and are boosted following infection but not vaccination [57]. While no  
396 differences were observed in this cohort with respect to levels of antibody isotypes to seasonal  
397 coronaviruses by infection status (**Figure 2, Figure S1**), there were significant correlations  
398 between antibodies to SARS-CoV-2 spike, and nucleoprotein and those to spike proteins of  
399 seasonal coronaviruses (**Figure 2F**). Age did not correlate with the magnitude of these seasonal  
400 coronavirus IgG antibodies (**Figure 4**). We also observed that OC43 and NL63 IgG levels  
401 correlated with activation of T cells with spike peptide pools, but not protein (**Figure 3**), indicating  
402 this peptide pool contained epitopes known to overlap with seasonal coronaviruses as previously  
403 reported [60] that was not observed with full protein.

404 Variable reduction analyses identified population clusters that differed significantly in their  
405 antibody isotypes to seasonal coronaviruses (IgG1, IgM, IgA in population 1 vs IgG2, IgG4 in  
406 population 2, **Figure 5, Figure S6, Table S2**), suggesting that these antibody responses,  
407 particularly IgM 229E and IgG1 OC43, may impact the development of SARS-CoV-2 immunity.  
408 IgM responses to 229E spike protein were negatively correlated with Th2 cytokines IL-4 and IL-  
409 10 post-infection (**Figure 5E**) and post-vaccination neutralization responses (**Figure 6D-E,**  
410 **Figure S7A-B**). IgG1 levels to OC43 spike protein negatively impacted neutralization responses  
411 within <3 months post-vaccination (**Figure 6D, Figure S7A-B**), but positively affected longevity  
412 of post-vaccination responses (**Figure 6E, Figure 7B**). Thus, we confirmed evidence that pre-  
413 existing to seasonal coronaviruses immunity shapes infection and vaccination responses to  
414 SARS-CoV-infection [57-59]. However, this effect differed by time post-vaccination and supported  
415 an important role for non-IgG1 isotypes (IgM, IgG3) to seasonal coronaviruses that warrants  
416 further study.

417 Study limitations primarily involved using SARS-CoV-2 infection to differentiate subjects rather  
418 than pre-pandemic samples. In addition, the assays were limited to peripheral blood samples and  
419 not tissue-specific responses, which included only effector functions to spike protein and cytokine  
420 secretion instead of T-cell subset analyses. Detection of secreted cytokines allowed a greater  
421 number of cytokines to be evaluated but prevented confirmation of cells producing cytokines as  
422 would be observed intracellular stained cytokines for specific T-cell populations. However,  
423 cytokines between spike or peptide pools were highly correlated (**Figure S5**), indicating T-cell  
424 production. Also, high expression of IL-2 has been routinely observed from CD4+ T-cell and not  
425 CD8+ T-cells after SARS-CoV-2 infection [28, 38]. In this study, IL-17A secretion was closely

426 correlated to IL-2 and Th1 cytokine release after stimulation with protein or peptide pools,  
427 suggesting that IL-17A may be serving as a proxy for a Th1/Th17 subset, as identified in other  
428 post-vaccination studies [61] which should be more closely examined. Finally, while the critical  
429 role for age in SARS-CoV-2 immunity was validated, it remains an ongoing question of why  
430 children exhibit less severity with infection and how differences in qualitative features of immunity  
431 depend on patient age.

432 Our study used samples collected from subjects only shortly after the pandemic which will be  
433 difficult to perform as COVID subsides and vaccination rates increase in the general population.  
434 Our findings indicate that SARS-CoV-2 specific humoral responses and functions are likely  
435 shaped by age, disease severity, quality of CD4+ T cell help, IgM or other non-IgG1 antibody  
436 isotypes to seasonal coronaviruses. SARS-CoV-2 specific T-cell responses, particularly IL-2  
437 secretion, can be their own correlate of protection. Further studies combining powerful systems  
438 serology tools with T-cell function measures with other cohorts, tissue types, and timeframes will  
439 continue to tease out how these factors contribute to the diversity in SARS-CoV-2 infection  
440 outcomes and duration of immunity, including risks of breakthrough infections.

441

#### 442 **Acknowledgements**

443 We sincerely thank the CSI study participants. Funding for this study was provided under NIH  
444 Project U54CA260581-01. Funding for CVM and SSD was supported by the Telomere Research  
445 Network, NIH Project 5U24AG066528 (SSD). The funders had no role in study design, data  
446 collection and analysis, decision to publish or preparation of the manuscript.

#### 447 **Author Contributions**

448  
449 Conceptualization, E.B.N., B.M.G., J.E.R, J.S.S., M.L.D., S.S.D., K.J.Z; Methodology, E.B.N.,  
450 B.M.G., J.E.R; Investigation, A.E.M., E.E., I.V.T., T.J.Y., S.B., S.C., D.H.E., A.R.S., S.N.H.,  
451 K.E.O., S.J.B., B.N. T.H.; Resources, M.L.D., C.Y.Z., I.V.T., C.V.M., S.E.C., A.A., A.E.S., M.J.G.,  
452 N.D.F., E.J.E., A.D.P., S.J.L.,J.K.K.; Data Curation, E.B.N., A.E.M., E.E., J.G.S.; Visualization,  
453 E.B.N., B.M.G., J.G.S.; Writing – Original Draft, E.B.N., B.M.G., A.E.M, EE, J.G.S.; Writing –  
454 Review & Editing, J.E.R., J.S.S., K.J.Z., J.G.S., J.K.K.; Funding Acquisition, E.B.N., B.M.G.,  
455 J.E.R, J.S.S.

456

457 **Declaration of Interests.** The authors declare no competing interests.

458

#### 459 **TABLE AND FIGURE LEGENDS**

460

461 **Table 1. Composition of study cohort by SARS-CoV-2 infection status.**

462

463 **Table S1. Study questionnaire on demographic and COVID-19 factors.**

464

465 **Figure 1. Cohort composition includes a range of asymptomatic or mild to moderate**  
466 **disease subjects.** (A) Days post-symptom onset or possible viral exposure for last SARS-CoV-  
467 2 PCR positive test for each subject and indicated day of first study visit. The bars represent the

468 median number of days. (B) Symptom score as a composite of major and minor COVID-19  
469 symptoms, range 0–21. Red circles indicate infected subjects and white circles indicate  
470 uninfected subjects. (C) Hierarchical clustering of individual subjects by symptoms with  
471 associated heatmap for reported symptom or infection and demographic information listed  
472 underneath (blue colors or color ranges indicate positive, high, female, or older age categories).  
473 Major symptoms are shown colored red. (D) PCA analysis of subject's infection and demographic  
474 data colored by SARS-CoV-2 infection status with eigenvalues and eigenvector variables shown  
475 for components 1 and 2.

476

477 **Figure 2. Antibody isotypes dictate effector functions post-infection.** (A) IgG1 responses to  
478 spike, RBD or N SARS-CoV-2 specific antigens and spike-specific responses to seasonal  
479 coronaviruses OC43, HKU1, 229E, NL63 for each subject by SARS-CoV-2 infection status. (B)  
480 IgG1 or IgG4 spike-specific expression by days post-infection or possible exposure with  
481 significant Spearman's correlations indicated. (C) Neutralization responses by SARS-CoV-2  
482 infection status. (D) ADNKA, ADCD, ADNP, or ADCP responses by SARS-CoV-2 infection status.  
483 (E) Correlation matrix for indicated measures with heatmaps of Spearman's rho values (left) and  
484 p values (right). (F) Network of indicated antibody responses with the color of connecting lines  
485 representing Spearman's rho values. Bars represent mean +/- SD. Significance by Mann Whitney  
486 indicated as  $p < 0.05$  (\*),  $< 0.01$  (\*\*), or  $< 0.001$  (\*\*\*). Area under the curve (AUC).

487

488 **Figure S1. Expanded humoral analysis of the study population.** (A) Strong concordance of  
489 results between spike and nucleoprotein IgG by Luminex-based analysis and ELISA optical  
490 density results. (B) Symptom score versus IgG1 responses to spike with Spearman's correlation  
491 indicated. (C) IgG2, IgG3, IgG4, IgA1, IgA2, IgM responses to spike, RBD or N SARS-CoV-2  
492 specific antigens, and spike-specific responses to seasonal coronaviruses OC43, HKU1, 229E,  
493 NL63 for each subject by SARS-CoV-2 infection status.

494

495 **Figure S2. Stability of cellular and humoral measures between multiple study visits.** (A)  
496 Schematic of original and return study visit by date for selected SARS-CoV-2 infected subjects  
497 ( $n=18$ ). Immune measures were compared between first and second subject visits (indicated by  
498 line) and the difference calculated for each subject with bar at the mean +/- SD; including: (B)  
499 spike IgG1, (C) spike IgA1, (D) neutralization responses, (E) CD4 T cell AIM to spike, (F) CD4 T  
500 cell AIM to spike peptide, (G) IL-2 secretion to spike, (H) IL-2 secretion to spike peptide (fold  
501 change from unstimulated), (I) IFN $\gamma$  secretion to spike, (J) IFN $\gamma$  secretion to spike peptide.  
502 Significance by Wilcoxon signed rank test indicated as  $p < 0.05$  (\*),  $< 0.01$  (\*\*), or  $< 0.001$  (\*\*\*).

503

504 **Figure S3. Individual subject responses.** (A) Pie charts of each subject by antibody functions  
505 and select cellular measures. Black boxes indicate subjects with evidence for cellular immunity  
506 without seroconversion. (B) CD4+ T cell AIM, CD8+ T cell AIM, IL-2 secretion, or IFN $\gamma$  secretion  
507 to spike protein by spike or nucleoprotein IgG serostatus.

508

509 **Figure 3. CD4 Th1 responses to spike, nucleoprotein, and matrix antigens strongly**  
510 **correlate with SARS-CoV-2 serum IgG and neutralization responses.** (A) Spike-specific AIM  
511 changes in CD4 or CD8 T cells by SARS-CoV-2 infection status (% of CD4 or CD8). CD8 T cell

512 AIM excludes three high responders in the SARS-CoV-2 infection group (values of 8.6, 14.7, and  
513 15.6). (B) T cell AIM results by day post-infection or possible exposure with significant Pearson's  
514 correlations indicated. (C) Pie charts of log-transformed mean cytokine levels to spike protein or  
515 peptide pools (spike, nucleoprotein or matrix) expressed as fold change from unstimulated with  
516 color key indicated. (D) Spike-specific IL-2 and IFN $\gamma$  cytokines secretion expressed as fold  
517 change from unstimulated by infection status. (E) Cytokine changes by day post-infection or  
518 possible exposure with significant Pearson's correlations indicated. (F) Number of IL-2, IFN $\gamma$ , or  
519 TNF $\alpha$  cytokines expressed at fold change >2.5 from unstimulated cells by SARS-CoV-2 infection  
520 status. (G) Correlation matrix for indicated measures with heatmaps of indicated Spearman's rho  
521 (left) and p values (right). Bars shown at mean +/- SD. Significance by Mann Whitney indicated  
522 as p<0.05 (\*), <0.01 (\*\*), or <0.001 (\*\*\*)  
523

524 **Figure S4. Measures of cellular immunity in study population.** (A) Example AIM analysis by  
525 gating CD134-high expression on CD4 T-cells (CD4+, CD8-, CD3+ DUMP- (dead/CD33) or CD69  
526 expression on CD8 T-cells (CD4-,CD8+,CD3+,DUMP-). (B) CD4 T cell AIM responses for mock  
527 and stimulated conditions for each subject (line) by infection status. (C) CD4 or CD8 T cells AIM  
528 to spike peptide pools by infection status. (D) CD8 T cell AIM responses for mock and stimulated  
529 conditions for each subject (line) by infection status. (E) Spike specific cytokine secretion  
530 expressed as a fold change from unstimulated cells by infection status. (F) Number of IL-2, IFN $\gamma$ ,  
531 or TNF $\alpha$  cytokines expressed at fold change >2.5 from unstimulated cells by day post infection or  
532 possible exposure. (G) Number of IL-2, IFN $\gamma$ , or TNF $\alpha$  cytokines expressed with antigen  
533 stimulation at fold change >4 from unstimulated cells by infection status. Bars at mean +/- SD.  
534 Significance by Mann Whitney test indicated as P<0.05 (\*), <0.01 (\*\*), or <0.001 (\*\*\*)  
535

536 **Figure S5. Strong correlation between stimulation antigens used for T-cell AIM and  
537 cytokine secretion assays.** Correlation matrix for indicated measures after stimulation with spike  
538 protein or spike, nucleoprotein, or matrix peptide pools stimulation displayed as heatmaps of  
539 indicated Spearman's p values (A) and rho correlation coefficient (B).  
540

541 **Figure 4. Age is a significant driver of disease severity and development of SARS-CoV-2  
542 immunity.** (A) Age of each subject, percent of individuals with chronic conditions, symptom score  
543 of each subject and percent of individuals that meet COVID-19 case definition by age category.  
544 (B) Correlation matrix for age, age category and sex (male = 1, female = 2) with heat maps of  
545 indicated Spearman's P or rho values. (C) Spike-specific responses for IgG1 and IgGA1, ADNP,  
546 and neutralization responses of each subject by age category. (D) CD8 AIM changes for spike  
547 protein or peptide pool and Granzyme B and IL-10 fold change for spike protein by age category.  
548 Significance by ANOVA with Dunn's post-test or logistic regression model with pairwise contrast  
549 indicated as P<0.05 (\*), <0.01 (\*\*), or <0.001 (\*\*\*)  
550

551 **Figure 5. SARS-CoV-2 immunity can be clustered into two populations based on age,  
552 Th1/Th2 responses, antibody isotypes, and effector functions.** (A) An imputed dataset for all  
553 SARS-Co-V immunologic variables was used for t-SNE analysis and then K-means clustering for  
554 comparison of variables. No seasonal coronavirus data, infection history or demographic data  
555 was used. All imputed data were required to have at least 60% of non-missing cell values. (B)

556 Graphs of demographic and SARS-CoV-2 infection variables defined by cluster. (C) Graphs of  
557 SARS-CoV-2 or seasonal coronavirus immunity variables defined by cluster. Significant Kruskal-  
558 Wallis test between tSNE clusters indicated by  $P < 0.05$  (\*),  $< 0.01$  (\*\*), or  $< 0.001$  (\*\*\*). (D) Dot plots  
559 by indicated measures for subjects included in cluster 1 (pink) or 2 (blue) with spline trend line  
560 (black) shown in log scale. (E) Correlation network across immune and disease features that were  
561 significantly associated across SARS-CoV-2 infected individuals.

562

563 **Table S2. Kruskal-Wallis analyses comparing t-SNE Cluster 1 and 2 populations and**  
564 **demographic, infection, or immunologic variables.**

565

566 **Figure S6. Supporting data for population clusters by SARS-CoV-2 immunity.** (A) Imputed  
567 dataset for all SARS-CoV immunologic variables was used for UMAP analysis. The blue and  
568 red shaded regions represent clusters of UMAP values determined by the K-means clustering  
569 approach. All imputed data were required to have at least 60% of non-missing cell  
570 values. (B) Graphs of demographic and SARS-CoV-2 infection variables with correlation  
571 significance to UMAP 1 or 2 indicated  $P < 0.05$  (\*). (C) Graphs of variables ( $P < 0.05$ ) significantly  
572 correlated with UMAP 1 or 2 at  $P < 0.05$ . (D) Additional tSNE analysis graphs color-coded with  
573 indicated variables for SARS-CoV-2 infected subjects only. (E) Correlation matrix for indicated  
574 measures with heatmaps of Spearman's rho values and p values by cluster 1 (right) or cluster 2  
575 (left). (F) Validation of key tSNE findings using unimputed dataset from SARS-CoV-2 infected  
576 subjects with spline trend line (blue or orange) shown all graphs in log scale except Th1 cytokines  
577 to Spike (number of  $> 2.5$  fold change for IL-2, IFN, TNF).

578

579 **Figure 6. Post-vaccination responses are predicted by SARS-CoV-2 immunity post-**  
580 **infection.** (A) Sample timeline for select subjects with SARS-CoV-2 infection who were followed  
581 for post-vaccination (PV) sample collections ( $n=32$ ). (B) Neutralization antibodies in these  
582 subjects pre- or post-initiation of vaccination colored by vaccine type. Spline trend line (black)  
583 shown for post-vaccination samples with Spearman's correlation indicated (for samples collected  
584 post-17 days). (C) Titers of neutralizing antibodies are plotted according to days from the  
585 completion of the primary vaccine series. (D-E) Predictive modeling with feature reduction  
586 analysis was used to determine the post-infection immune features that predicted neutralizing  
587 antibody titers across all post-vaccination time points (D) or  $> 3$  months (E). The selected features  
588 that best predicted post-vaccine neutralizing antibody titers in a partial least squares regression  
589 analysis are shown in (i), and features with a VIP score  $> 0.8$  were used in a principal component  
590 analysis (ii). (F) Post-vaccination neutralizing antibody titers in samples from subjects from cluster  
591 1 or cluster 2. Mann-Whitney analysis was used to determine statistical significance as indicated  
592 or  $P < 0.001$  (\*\*\*).

593

594 **Figure S7. Expanded analysis of post-infection immune features that predict or correlate**  
595 **with neutralizing antibody titers after vaccination.** (A) Predictive modeling with feature  
596 reduction analysis was used to determine if specific post-infection immune features predicted  
597 post-vaccine neutralizing antibody titers  $< 3$  months. The selected features that best predicted  
598 post-vaccine neutralizing antibody titers in a partial least squares regression analysis are shown  
599 in (i), and features with a VIP score  $> 0.8$  were used in a principal component analysis (ii). (B)

600 Correlation matrix for post-infection/pre-infection immune measures to post-vaccination  
601 neutralization responses with heatmaps of indicated Spearman's rho and p values for all samples  
602 or >90 days samples from completion of vaccination series. (C) Graphs of select measures from  
603 post-infection/pre-infection immune measures to post-vaccination neutralization responses for all  
604 samples or >90 days samples from completion of vaccination series.  
605

## 606 **Methods**

607

### 608 **Study design and subject recruitment**

609 The study was a rolling prospective cohort of subjects recruited from communities in New Orleans  
610 between June 2020 to February 2021. Subjects or households with suspected or confirmed  
611 SARS-CoV-2 infection were recruited from the Greater New Orleans community under Tulane  
612 Biomedical Institutional Review Board (federalwide assurance number FWA00002055, under  
613 study number 2020-585). Enrolled subjects completed a study questionnaire regarding infection  
614 and demographic information and provided a blood sample. A subsample of subjects returned for  
615 a follow-up visit.  
616

617

### 617 **SARS-CoV-2 infection and COVID-19 case classification**

618 History of SARS-CoV-2 infection was defined as 1) clear evidence of immunity (SARS-CoV-2 S  
619 or N-specific IgG), or 2) detection of plasma viral RNA as described below, or 3) fulfillment of the  
620 Centers for Disease Control and Prevention (CDC) case definition of confirmed or probable  
621 COVID-19 infection (an individual with a) confirmatory or presumptive laboratory criteria including  
622 history of positive SARS-CoV-2 PCR or antigen test or b) absence of negative PCR/antigen test  
623 that was performed 2 days prior to 5 days after onset of symptoms and clinical criteria with certain  
624 symptoms and fulfill the epidemiological criteria with exposure to a family or household contact  
625 with known SARS-CoV-2 [62]).  
626

627

### 627 **Symptoms and illness severity scores**

628 A general symptom score was calculated according to the September 2021 CDC classification  
629 (prior to circulation of the Omicron variant). Two points were given according to each major  
630 symptom: cough, shortness of breath, difficulty breathing, loss of smell, and loss of taste. One-  
631 half of a point was given for each minor symptom: fever, runny nose, nasal congestion, sore  
632 throat, diarrhea, vomiting, fatigue, muscle aches, chills, nausea, and headache. Total symptom  
633 score was calculated as the sum of the major and minor scores.  
634

635

635 Because illness severity is not necessarily measurable by the point-based approach used for the  
636 general symptom score, it was calculated according to clinical manifestations thresholds based  
637 on lung involvement and impairments, as detailed in Baj et al. (2020, [63]). Specifically, the  
638 severity score was defined as severe (abdominal pain, shortness of breath, difficulty breathing,  
639 chest pain, vomiting, nausea, diarrhea); moderate (fever, cough, runny nose, fatigue, muscle  
640 aches, loss of smell, headache, sore throat, loss of taste, nasal congestion, chills, repeated chills,  
641 hair loss, toes); and asymptomatic (no reported symptoms). Hair loss was considered to be



642 typically associated with long-term COVID-19 symptoms and thus was not considered as an  
643 acute, severe symptom.

644

#### 645 **Continuous predictors**

646 Age was based on self-reported birth date at study enrollment. Body mass index (BMI) was  
647 defined as weight in kilograms divided by height in meters squared. For adults, BMI was  
648 calculated as: as <18.5 (underweight), 18.5-30 (normal), and >30 (overweight/obese). For  
649 children (aged under 18 years), BMI was calculated as <5<sup>th</sup> percentile (underweight), between the  
650 5<sup>th</sup> and 95<sup>th</sup> percentile (normal), and greater than the 95<sup>th</sup> percentile (overweight/obese).

651

#### 652 **Sample collections**

653 Blood was collected from subjects and plasma and peripheral blood mononuclear cells (PBMCs)  
654 and were isolated by density gradient centrifugation in Leukosep tubes (Greiner Bio One) and  
655 Ficol-Paque PREMIUM 1.078g/ml (Cytiva) [64, 65]. Plasma was removed and stored at  
656 -80°C or heat-inactivated at 56°C for 30mn before testing. PBMC were washed, counted, and  
657 suspended in FBS-10% DMSO at  $1 \times 10^7$  cells/ml. Aliquots of cells were frozen at -80C in a  
658 Nalgene Mr. Frosty container (Nalgene Labware, Rochester, NY) before final storage in liquid  
659 nitrogen.

660

#### 661 **Plasma viral RNA detection**

662 RNA viral load was measured with a sensitive SARS-CoV-2 specific CRISPR assay as previously  
663 reported [33, 34]. Twice the limit of viral detection, or  $2 \times 10^6$  as RNA abundance expressed as the  
664 relative photoluminescence intensity of the sample was used as definitive evidence of SARS-  
665 CoV-2 infection.

666

#### 667 **Determination of antigen-specific antibody reactivity by multiplexed Luminex analysis.**

668 Recombinant SARS-CoV-2 antigens (full-length spike, RBD, and N) and the recombinant spike  
669 protein from OC43, HKU1, 229E, and NL63 (Frederick National Laboratories) were coupled with  
670 MagPlex beads (Luminex) via sulfo-NHS coupling chemistry. Heat-inactivated samples were  
671 diluted at 1:50 in 1X PBS + 0.1% bovine serum albumin (BSA) + 0.05% Tween20 and incubated  
672 with antigen-coupled beads for 2 hours. Beads were washed and incubated with 0.65µg/ml of PE-  
673 labeled secondary antibodies specific for the human antibody subclasses IgG1 (Clone HP6001;  
674 Southern Biotech), IgG2 (Clone HP6002; Southern Biotech), IgG3 (Clone HP6050; Southern  
675 Biotech), IgG4 (Clone HP6025; Southern Biotech), IgA1 (Clone B3506B4; Southern Biotech) IgA2  
676 (Clone A9604D2; Southern Biotech), IgM (Clone UHB, Southern Biotech) for 1 hour at room  
677 temperature. Beads were washed three times with assay buffer and analyzed on a MagPix  
678 instrument (Luminex, Austin, TX). The median fluorescent intensity for 50 beads/region was  
679 recorded. SARS-CoV-2 seronegative plasma samples were used to establish baseline reactivity  
680 and thresholds for positivity.

681

#### 682 **ELISA and Neutralization assays**

683 Recombinant SARS-CoV-2 spike for use in ELISAs was produced in-house by stable expression  
684 of a modified phCMV based plasmid that encodes the pre-fusion trimeric SARS CoV-2 spike  
685 protein with the D614G mutation (kindly provided by Dr. Kate Hastie (La Jolla Institute for

686 Immunology)[66, 67]). Stable expression was maintained via blasticidin selection in stably  
687 transfected 293F cells. Recombinant protein was purified from clarified culture medium by affinity  
688 chromatography on Streptactin X affinity columns. RBD (aa321-535) was similarly expressed in  
689 the pHCMV plasmid and purified on Streptactin X affinity columns.

690  
691 A DNA fragment encoding SARS CoV-2 N protein, including its natural leader sequence was  
692 generated by PCR of full-length N protein gene from a lentiviral N Protein expression vector  
693 (pLVX-EF1alpha-SARS-CoV-2-N-2xStrep-IRES-Puro, which was a gift from Nevan Krogan  
694 (Addgene plasmid # 141391 ; <http://n2t.net/addgene:141391>; RRID:Addgene\_141391, [68]). This  
695 fragment was inserted in place of the RBD sequence in the above expression plasmid upstream  
696 of the double strep-tag sequence using NEB gene builder.

697  
698 Wells of 96-well ELISA plates (Costar, Easy Wash) were coated for 1 hour at room temperature  
699 with purified SARS CoV-2 spike protein (500 ng/ml in 100 mM sodium bicarbonate buffer). Wells  
700 were washed X 5 and blocked for 1 hour at +37°C. Blocking and dilution buffers consisted of  
701 0.5%Tween +5% dry milk+ 4%whey protein (BiPro, Le Sueur, MN) +10%FBS in 1xPBS. After  
702 wells had been washed and blocked, 100 ul heat-inactivated sera or plasma samples diluted to  
703 1:100 were incubated in antigen-coated and uncoated wells for 1 hour. Wash buffer consisted  
704 of PBS with 500 mM NaCl and 0.2% Triton X. The higher salt content of the wash buffer greatly  
705 reduced background noise. Bound IgG was detected with peroxidase-conjugated goat anti-IgG  
706 (Jackson ImmunoResearch) and diluted at 1:15,000. Color was developed with TMB-H202 and  
707 stopped with 1 M phosphoric acid. Absorbance (optical density [OD]) was read at 450 nm. In  
708 experiments where samples were tested in wells with and without spike protein, net ODs were  
709 calculated by subtracting background OD readings from OD readings with spike protein. Cut-off  
710 OD values were then calculated based on testing of >100 pre-COVID-19 samples. Net OD values  
711 >0.5 were considered positive. The Spike protein ELISA for IgG antibodies has been validated by  
712 testing a standard set of positive and negative samples provided by NCI SeroNet staff. These  
713 validations showed sensitivity and specificity for the immunoassay as 98% and 100%, respectively).

714  
715 Similar ELISAs were run with purified RBD and N protein-coated in wells. For the RBD ELISA,  
716 protein was coated at 500 ng/ml in 100 ul of 100 mM sodium bicarbonate. For the N protein ELISA,  
717 protein was coated at 2 ug/ml. Otherwise, the ELISA procedure was the same as for the spike  
718 protein ELISA.

#### 719 720 **Neutralization of SARS CoV-2 in Pseudovirus Assay**

721 CHO cells were generated and stably expressed ACE2 by transfecting CHO cells with an ACE2  
722 expression plasmid containing the blasticidin resistance gene. ACE2 expressing cells were  
723 selected in medium containing 10 ug/ml blasticidin ml. Blasticidin-resistant cells were expanded  
724 and selected for high level ACE2 expression by flow cytometry of cells binding a FITC-labeled  
725 murine Mab to ACE2 (Sino Biologicals Cat # 10108-MM37-F). ACE2 positive cells have been  
726 sorted twice and have stably expressed ACE2 through multiple passages over 4–5 months with  
727 gradual diminishment of luciferase signal induced by pseudovirus infection. Cell lines were  
728 cryopreserved, and, as needed, cells were periodically thawed and freshly grown for continued

729 studies. CHO-ACE2 cells were similar in SARS CoV-2 susceptibility to the 293T/ACE2 cell line  
730 developed by Dr. Farzan [69] but have better adherence to tissue culture surfaces.

731 SARS-CoV-2 neutralizing antibodies were assessed in serum or plasma samples with sensitive,  
732 high-throughput pseudovirus assays. Virus neutralization was measured in CHO/ACE2 cells. The  
733 pseudovirus assay was originally developed by Drs. Barney Graham and others at Vaccine  
734 Research Center at the National Institutes of Health (NIH). The assay was formally optimized and  
735 validated in Dr. David Montefiori's laboratory at Duke University. The materials and protocol were  
736 kindly provided to the Robinson lab by Drs. Graham and Montefiori.

737 For pseudovirus production, four expression plasmids were obtained from NIH Vaccine Research  
738 Center. These included an expression plasmid for full-length spike protein of the Wuhan-1 strain  
739 containing the D614G amino acid chain (VRC7480.G614) [70], a pCMV  $\Delta$ R8.2 lentivirus  
740 backbone plasmid (VRC5602) [71], the VRC5601 plasmid pHR' CMV Luc containing the firefly  
741 luciferase reporter gene [71], and VRC9260 for TMPRSS2 expression. Pseudoviruses were  
742 produced by co-transfection of the four plasmids into 293T cells grown in T75 flasks with Fugene  
743 6 as transfection reagent. Virus stocks are collected 3 days after transfection, clarified, passed  
744 through a 0.45  $\mu$ m filter, and stored in aliquots at  $-80^{\circ}\text{C}$ .

745 For neutralization, a predetermined optimal dose of pseudovirus was incubated with 8 serial 3-  
746 fold dilutions of heat-inactivated serum or plasma samples in 150  $\mu$ l medium for 1 h at  $37^{\circ}\text{C}$  in  
747 96-well tissue culture plates. CHO/ACE2 cells, suspended by the action of TrypLE enzyme, were  
748 added to wells (10,000 cells in 100  $\mu$ L medium per well). One set of eight control wells received  
749 cells + virus (virus control), and another set of eight wells received cells only (background control).  
750 After 66-72 hours of incubation, the medium was removed by gentle aspiration. Then, 100  $\mu$ l of  
751 1:6 dilution of Promega BriteGlo in Glo lysis buffer was added to the wells with mixing. Plates  
752 were incubated for 7 minutes at room temperature, after which luminescence was measured in a  
753 Biotek Synergy H1 Luminometer. Neutralization titers were defined as the serum dilution (ID50)  
754 at which relative luminescence units (RLU) were reduced by 50% compared to virus control wells  
755 after subtraction of background RLUs (determined by GraphPad Prism, version 9 for macOS,  
756 GraphPad Software, San Diego, California USA).

#### 757 **Determination of Spike and Nucleoprotein IgG seropositivity**

758 ELISA and Luminex results were compared for Spike or Nucleoprotein seropositivity for IgG or  
759 IgG1, respectively. Any consistent results, disagreements or borderline positive/negative results  
760 were coded as indeterminant.

761

#### 762 **Antibody-dependent NK cell degranulation and activation.**

763 NK92 cells (ATCC CRL-2407) expressing CD16 were cultured in alphaMEM (Gibco; Cat# 12000-  
764 022) supplemented with 12.5% FBS (Hyclone SH30071.03), 12.5% horse serum (Hyclone; Cat#  
765 SH30074.03), 1.5g/L sodium bicarbonate (Fisher Sci; Cat# S-233-500), 0.02 mM Folic acid (Alfa  
766 Aesar; Cat# J62937), 0.2 mM Inositol (MP Biomedical; Cat# 194688), 0.1 mM Beta-  
767 mercaptoethanol (Gibco; Cat# 21985-023), 100 U/ml recombinant IL-2 (StemCell; Cat# 78036.3).  
768 Recombinant SARS-CoV-2 spike was coated onto MaxiSorp 96-well plates (Thermo Scientific

769 Cat# 442404) at 300 ng/well at 4°C overnight. Wells were washed with PBS and blocked with 5%  
770 BSA. Serum samples diluted 1:50 in PBS were added to the wells and incubated for 2 h at 37 °C.  
771 Unbound antibodies were removed by washing wells with PBS. NK92 cells in complete alphaMEM  
772 culture medium were added at  $5 \times 10^4$  cells/well in the presence of 4 µg/ml brefeldin A (Biolegend  
773 Cat# 420601), 5 µg/ml GolgiStop (BD Biosciences Cat# 554724) and 0.15µg of anti-CD107a  
774 antibody (Clone H4A3 PE-Cy7, Biolegend Cat# 328618) for 5 hours at 37°C. Cells were stained  
775 for surface expression of CD16 (Clone 3G8 Pacific Blue, Biolegend Cat# 302032) and CD56  
776 (clone 5.1H11 AlexaFluor488 Biolegend, Cat# 362518). Cells were fixed and permeabilized with  
777 Fix/Perm (Biolegend Cat# 421002) according to the manufacturer's instructions and stained for  
778 intracellular IFN $\gamma$  (Clone B27 PE, Biolegend Cat# 506507), and TNF $\alpha$  (clone Mab11 APC,  
779 Biolegend Cat# 502912). Cells were analyzed on a Cytex Aurora spectral flow cytometer.

780

### 781 **Antibody-dependent neutrophil phagocytosis (ADNP)**

782 Protocol was adapted from [72]. Recombinant biotinylated SARS-CoV-2 spike protein was  
783 coupled to Neutravidin fluorescent beads (LifeTechnologies). Serum samples diluted 1:100 in  
784 culture medium were incubated with spike-coated beads for 2h at 37°C. Freshly isolated white  
785 blood cells from human donor peripheral blood ( $5 \times 10^4$  cells/well) were added to wells and  
786 incubated for 1 hour at 37°C. Cells were stained for CD66b (Clone G10F5; Biolegend), CD3  
787 (Clone UCHT1; BD Biosciences), and CD14 (Clone MjP9; BD Biosciences), fixed with 4%  
788 paraformaldehyde, and analyzed by flow cytometry on a Cytex Aurora spectral flow cytometer.  
789 Neutrophils were defined as SSC-Ahigh CD66b+, CD3neg, CD14neg. A phagocytic score was  
790 determined using the following formula: (percentage of bead+ cells)\*(geometric mean fluorescent  
791 intensity (gMFI) of red bead+ cells)/10,000.

792

### 793 **Antibody-dependent cellular phagocytosis by human monocytes (ADCP)**

794 Protocol was adapted from [73]. THP-1 monocytes were maintained in RPMI-1640 supplemented  
795 with 10% FBS, penicillin/streptomycin (Gibco Cat#15070063), L-glutamine, and b-  
796 mercaptoethanol. Recombinant SARS-CoV-2 spike-coated beads were generated as described  
797 for ADNP. Serum samples were diluted in a five-fold dilution curve in THP-1 culture medium  
798 (1:2500, 1:12500, 1:62500) and incubated with spike-coated beads for 2 h at 37 °C. Unbound  
799 antibodies were removed by centrifugation before adding THP-1 cells at  $2.5 \times 10^4$  cells/well. Cells  
800 were fixed with 4% paraformaldehyde and analyzed by flow cytometry for uptake of fluorescent  
801 beads on a Cytex Aurora spectral flow cytometer. A phagocytic score was determined as  
802 described above, and the areas under the curve for the three dilutions were calculated.

803

### 804 **Antibody-mediated complement deposition (ADCD)**

805 Protocol was adapted from [74]. Recombinant SARS-CoV-2 spike-coated beads were generated  
806 as described for ADNP. Serum samples were diluted in culture medium 1:10 and incubated with  
807 spike-coated beads for 2 hours at 37 °C. Unbound antibodies were removed by centrifugation  
808 prior to the addition of reconstituted guinea pig complement (Cedarlane Labs CL4051) diluted in  
809 veronal buffer supplemented with calcium and magnesium (Boston Bioproducts) for 20 min at  
810 37°C. Beads were washed with PBS containing 15 mM EDTA and stained with an FITC-  
811 conjugated anti-guinea pig C3 antibody (MP Biomedicals). C3 deposition onto beads was

812 analyzed by flow cytometry on a Cytex Aurora spectral flow cytometer. The gMFI of FITC of all  
813 beads was measured.

814

#### 815 **PBMC restimulation and culture**

816  $6-7.2 \times 10^5$  PBMCs were cultured for 24 h in the presence of Spike Glycoprotein 0.2 µg/well (BEI,  
817 NR-52308, produced under HHSN272201400008C and obtained through BEI Resources, NIAID,  
818 NIH: Spike Glycoprotein (stabilized) from SARS-Related Coronavirus 2, Wuhan-Hu-1 with C-  
819 Terminal Histidine Tag, Recombinant from Baculovirus), and SARS-CoV-2 specific mega pools  
820 at 0.2 µg/well including PepTivator SARS-CoV-2 Prot\_S (Miltinyi - 130-126-700), SARS-CoV-2  
821 Prot\_M (130-126-702), SARS-CoV-2 Prot\_N (130-126-699) in 96-well U bottom tissue culture  
822 plate (CytoOne CC7672-7596) in 200 µl RPMI-1640 with 10% FBS. Media was used as a negative  
823 control. Supernatants were harvested at 24 h post-stimulation for multiplex cytokines detection  
824 and stored at -80°C.

825

#### 826 **Activation-induced marker (AIM) staining & detection**

827 Restimulated cells from above were pelleted and stained with Fixable Viability Dye eFluor™ 780  
828 in DPBS (eBioscience) for 30 minutes at 4C in the dark, then washed and resuspended in 50  
829 µl with an antibody cocktail in Brilliant Stain Buffer (Biosciences) [75, 76] for 30 minutes at 4C.  
830 Cells were then washed with flow buffer (500 ml 1x PBS ThermoFisher 20012-027, 5 g BSA  
831 Roche 10735078001, 0.5 g Sodium Azide Sigma S2002) and fixed for 20 minutes at 4C with  
832 10% formalin (polyScience 04018-1). Following fixation, cells were washed and resuspended in  
833 200 µl flow buffers. All samples were acquired on a BD LSRFortessa. A list of antibodies used in  
834 this panel can be found table 1 below:

835

Table 1. Cellular antibodies used for AIM assay.			
<u>Stain</u>	<u>Source</u>	<u>Catalog number</u>	<u>Antibody</u>
FITC	BioLegend	356914	anti-CD185
AF700	BioLegend	344724	anti-CD8
PE-Cy7	BioLegend	300914	anti-CD8a
BV510	BioLegend	317444	anti-CD4
FITC	BioLegend	310904	anti-CD69
APC-Cy7	BioLegend	366614	anti-CD33
PerCP-Cy5.5	Invitrogen	45-0338-42	anti-CD33
PE	BioLegend	350004	anti-CD134
PE-Cy7	BioLegend	300420	anti-CD3
eFlour450	Invitrogen	48-0037-42	anti-CD3
APC	BioLegend	309810	anti-CD137
APC-CY7	ThermoFisher	65-0865-14	Live/Dead

*Note.* All samples were acquired on a BD LSRFortessa.

836

#### 837 **Cytokine testing**

838 Cytokine test kits were used to measure cytokine levels in supernatant fluids from restimulated  
839 PBMC cultures according to manufacturers' protocol. Kit types included Bio-plex Pro Human  
840 Cytokine 17-plex (Biorad) or custom human (Biorad Bio-plex IFN- $\gamma$ , IL-2, IL-5, IL-6, TNF $\alpha$ ;  
841 Biologend Legendplex Perforin, and Granzyme B, BAFF, MIP-1 $\beta$ , IL-4, IL-10, IL-13, IL-15, IL-  
842 17A). Samples tested with the Legend-plex kit were reanalyzed with the standards for each  
843 cytokine with the best range. Results from comparing cytokine levels in stimulated and mock  
844 stimulated cultures were expressed as fold change. This calculation reduced batch effects among  
845 experiments. Values of zero from bio-plex kits were replaced with 0.1 or 1 (TNF- $\alpha$  only) or for  
846 Legend-plex kits with 0.1 or 1 (MIP-1 $\beta$  and BAFF only).

847

### 848 **Statistical Analysis**

849 Continuous data were expressed as means and standard deviations, medians and ranges, or  
850 medians and interquartile ranges. Categorical data were presented as frequencies and  
851 percentages. General comparisons among continuous predictors were performed using Kruskal-  
852 Wallis test with Dunn's post-tests for pairwise comparisons. General comparisons for categorical  
853 responses were performed using Pearson's chi-square test (or Fisher's Exact test where the  
854 assumption of a normal approximation to the binomial distribution was not justified). Pairwise  
855 comparisons for categorical responses were performed using logistic regression model contrasts.  
856 Dimensionality reduction was performed using t-Distributed Stochastic Neighbor Embedding [t-  
857 SNE] and Uniform Manifold Approximation and Projection [UMAP]) using the JMP Embedding  
858 Add On [77]. Feature selection using lasso regression was performed in JMP Pro 16. Lasso-  
859 selected features were used in a partial least square regression analysis with a leave-one-out  
860 validation method in JMP Pro 16. Features with a variable importance in projection score (VIP)  
861 >0.8 were used to generate a principal component analysis in JMP Pro 16. Data management  
862 and statistical analyses were carried out using the FloJo (version 10 Becton, Dickinson and  
863 Company, Ashland, OR), R (Version 4.1.2, R Foundation for Statistical Computing, Vienna,  
864 Austria) GraphPad Prism (version 9.0.0, GraphPad Software, San Diego, CA), JMP (version  
865 16.2.0, SAS Institute, Inc., Cary, NC), and SAS (version 9.4, SAS Institute, Inc., Cary, NC). The  
866 type I error threshold was set at 5%.

867

### 868 **Data imputation for dimension reduction analyses**

869 Data were singly imputed for tSNE and UMAP analyses using mean imputation for continuous  
870 variables and mode imputation for categorical variables. All imputed data were required to have  
871 at least 60% of non-missing cell values. Those variables not including at least 60% of observed  
872 data were excluded from the dimension reduction analyses.

873

874

875

### 876 **REFERENCES**

877

- 878 1. Kojima, N. and J.D. Klausner, *Protective immunity after recovery from SARS-CoV-2*  
879 *infection*. *Lancet Infect Dis*, 2022. **22**(1): p. 12-14.
- 880 2. Bange, E.M., et al., *CD8(+) T cells contribute to survival in patients with COVID-19 and*  
881 *hematologic cancer*. *Nat Med*, 2021. **27**(7): p. 1280-1289.

- 882 3. Cohen, B., et al., *COVID-19 infection in 10 common variable immunodeficiency patients in*  
883 *New York City*. J Allergy Clin Immunol Pract, 2021. **9**(1): p. 504-507 e1.
- 884 4. Grifoni, A., et al., *Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with*  
885 *COVID-19 Disease and Unexposed Individuals*. Cell, 2020. **181**(7): p. 1489-1501 e15.
- 886 5. Le Bert, N., et al., *SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and*  
887 *uninfected controls*. Nature, 2020. **584**(7821): p. 457-462.
- 888 6. Israelow, B., et al., *Adaptive immune determinants of viral clearance and protection in*  
889 *mouse models of SARS-CoV-2*. Sci Immunol, 2021. **6**(64): p. eabl4509.
- 890 7. McMahan, K., et al., *Correlates of protection against SARS-CoV-2 in rhesus macaques*.  
891 Nature, 2021. **590**(7847): p. 630-634.
- 892 8. Yang, H.S., et al., *Association of Age With SARS-CoV-2 Antibody Response*. JAMA Netw  
893 Open, 2021. **4**(3): p. e214302.
- 894 9. Bajaj, V., et al., *Aging, Immunity, and COVID-19: How Age Influences the Host Immune*  
895 *Response to Coronavirus Infections?* Front Physiol, 2020. **11**: p. 571416.
- 896 10. Bartsch, Y.C., et al., *Humoral signatures of protective and pathological SARS-CoV-2*  
897 *infection in children*. Nat Med, 2021. **27**(3): p. 454-462.
- 898 11. Chou, J., P.G. Thomas, and A.G. Randolph, *Immunology of SARS-CoV-2 infection in*  
899 *children*. Nat Immunol, 2022. **23**(2): p. 177-185.
- 900 12. Cohen, C.A., et al., *SARS-CoV-2 specific T cell responses are lower in children and increase*  
901 *with age and time after infection*. Nat Commun, 2021. **12**(1): p. 4678.
- 902 13. Rydzynski Moderbacher, C., et al., *Antigen-Specific Adaptive Immunity to SARS-CoV-2 in*  
903 *Acute COVID-19 and Associations with Age and Disease Severity*. Cell, 2020. **183**(4): p.  
904 996-1012 e19.
- 905 14. Weisberg, S.P., et al., *Distinct antibody responses to SARS-CoV-2 in children and adults*  
906 *across the COVID-19 clinical spectrum*. Nat Immunol, 2021. **22**(1): p. 25-31.
- 907 15. Garrido, C., et al., *Asymptomatic or mild symptomatic SARS-CoV-2 infection elicits durable*  
908 *neutralizing antibody responses in children and adolescents*. JCI Insight, 2021. **6**(17).
- 909 16. Klein, S.L., et al., *Sex, age, and hospitalization drive antibody responses in a COVID-19*  
910 *convalescent plasma donor population*. J Clin Invest, 2020. **130**(11): p. 6141-6150.
- 911 17. Long, Q.X., et al., *Clinical and immunological assessment of asymptomatic SARS-CoV-2*  
912 *infections*. Nature Medicine 2020.
- 913 18. Wang, P., et al., *SARS-CoV-2 neutralizing antibody responses are more robust in patients*  
914 *with severe disease*. Emerg Microbes Infect, 2020. **9**(1): p. 2091-2093.
- 915 19. Bergwerk, M., et al., *Covid-19 Breakthrough Infections in Vaccinated Health Care Workers*.  
916 N Engl J Med, 2021. **385**(16): p. 1474-1484.
- 917 20. Cromer, D., et al., *Neutralising antibody titres as predictors of protection against SARS-*  
918 *CoV-2 variants and the impact of boosting: a meta-analysis*. Lancet Microbe, 2022. **3**(1):  
919 p. e52-e61.
- 920 21. Khoury, D.S., et al., *Neutralizing antibody levels are highly predictive of immune protection*  
921 *from symptomatic SARS-CoV-2 infection*. Nat Med, 2021. **27**(7): p. 1205-1211.
- 922 22. *Science Brief: SARS-CoV-2 Infection-induced and Vaccine-induced Immunity*, in *CDC*  
923 *COVID-19 Science Briefs*. 2020: Atlanta (GA).
- 924 23. Zohar, T., et al., *Compromised Humoral Functional Evolution Tracks with SARS-CoV-2*  
925 *Mortality*. Cell, 2020. **183**(6): p. 1508-1519 e12.

- 926 24. Le Bert, N., et al., *Highly functional virus-specific cellular immune response in*  
927 *asymptomatic SARS-CoV-2 infection*. J Exp Med, 2021. **218**(5).
- 928 25. Liu, W.J., et al., *T-cell immunity of SARS-CoV: Implications for vaccine development against*  
929 *MERS-CoV*. Antiviral Res, 2017. **137**: p. 82-92.
- 930 26. Moss, P., *The T cell immune response against SARS-CoV-2*. Nat Immunol, 2022. **23**(2): p.  
931 186-193.
- 932 27. Jung, J.H., et al., *SARS-CoV-2-specific T cell memory is sustained in COVID-19 convalescent*  
933 *patients for 10 months with successful development of stem cell-like memory T cells*. Nat  
934 Commun, 2021. **12**(1): p. 4043.
- 935 28. Peng, Y., et al., *Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-*  
936 *2 in UK convalescent individuals following COVID-19*. Nat Immunol, 2020. **21**(11): p. 1336-  
937 1345.
- 938 29. Mok, C.K.P., et al., *T-cell responses to MERS coronavirus infection in people with*  
939 *occupational exposure to dromedary camels in Nigeria: an observational cohort study*.  
940 Lancet Infect Dis, 2021. **21**(3): p. 385-395.
- 941 30. Bergamaschi, L., et al., *Longitudinal analysis reveals that delayed bystander CD8+ T cell*  
942 *activation and early immune pathology distinguish severe COVID-19 from mild disease*.  
943 Immunity, 2021. **54**(6): p. 1257-1275 e8.
- 944 31. Notarbartolo, S., et al., *Integrated longitudinal immunophenotypic, transcriptional and*  
945 *repertoire analyses delineate immune responses in COVID-19 patients*. Sci Immunol, 2021.  
946 **6**(62).
- 947 32. Nelson, C.E., et al., *Mild SARS-CoV-2 infection in rhesus macaques is associated with viral*  
948 *control prior to antigen-specific T cell responses in tissues*. Sci Immunol, 2022: p.  
949 eabo0535.
- 950 33. Huang, Z., et al., *Sensitive tracking of circulating viral RNA through all stages of SARS-CoV-*  
951 *2 infection*. J Clin Invest, 2021. **131**(7).
- 952 34. Huang, Z., et al., *Ultra-sensitive and high-throughput CRISPR-powered COVID-19*  
953 *diagnosis*. Biosens Bioelectron, 2020. **164**: p. 112316.
- 954 35. Bergamaschi, C., et al., *Systemic IL-15, IFN-gamma, and IP-10/CXCL10 signature*  
955 *associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine*  
956 *recipients*. Cell Rep, 2021. **36**(6): p. 109504.
- 957 36. Pegu, A., et al., *Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2*  
958 *variants*. Science, 2021. **373**(6561): p. 1372-1377.
- 959 37. Levin, E.G., et al., *Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over*  
960 *6 Months*. N Engl J Med, 2021. **385**(24): p. e84.
- 961 38. Rodda, L.B., et al., *Functional SARS-CoV-2-Specific Immune Memory Persists after Mild*  
962 *COVID-19*. Cell, 2021. **184**(1): p. 169-183 e17.
- 963 39. Zeng, F., et al., *Over 1-year duration and age difference of SARS-CoV-2 antibodies in*  
964 *convalescent COVID-19 patients*. J Med Virol, 2021. **93**(12): p. 6506-6511.
- 965 40. Lau, E.H.Y., et al., *Neutralizing antibody titres in SARS-CoV-2 infections*. Nat Commun,  
966 2021. **12**(1): p. 63.
- 967 41. Wu, J., et al., *SARS-CoV-2 infection induces sustained humoral immune responses in*  
968 *convalescent patients following symptomatic COVID-19*. Nat Commun, 2021. **12**(1): p.  
969 1813.




- 970 42. Jin, C.C., et al., *Correlation between viral RNA shedding and serum antibodies in individuals*  
971 *with coronavirus disease 2019*. Clin Microbiol Infect, 2020. **26**(9): p. 1280-1282.
- 972 43. Lofano, G., et al., *Antigen-specific antibody Fc glycosylation enhances humoral immunity*  
973 *via the recruitment of complement*. Sci Immunol, 2018. **3**(26).
- 974 44. Ouchida, R., et al., *Critical role of the IgM Fc receptor in IgM homeostasis, B-cell survival,*  
975 *and humoral immune responses*. Proc Natl Acad Sci U S A, 2012. **109**(40): p. E2699-706.
- 976 45. Pusnik, J., et al., *Memory B cells targeting SARS-CoV-2 spike protein and their dependence*  
977 *on CD4(+) T cell help*. Cell Rep, 2021. **35**(13): p. 109320.
- 978 46. Juno, J.A., et al., *Humoral and circulating follicular helper T cell responses in recovered*  
979 *patients with COVID-19*. Nat Med, 2020. **26**(9): p. 1428-1434.
- 980 47. Kared, H., et al., *SARS-CoV-2-specific CD8+ T cell responses in convalescent COVID-19*  
981 *individuals*. J Clin Invest, 2021. **131**(5).
- 982 48. Oberhardt, V., et al., *Rapid and stable mobilization of CD8(+) T cells by SARS-CoV-2 mRNA*  
983 *vaccine*. Nature, 2021. **597**(7875): p. 268-273.
- 984 49. Larsen, M.D., et al., *Afucosylated IgG characterizes enveloped viral responses and*  
985 *correlates with COVID-19 severity*. Science, 2021. **371**(6532).
- 986 50. Hoepel, W., et al., *High titers and low fucosylation of early human anti-SARS-CoV-2 IgG*  
987 *promote inflammation by alveolar macrophages*. Sci Transl Med, 2021. **13**(596).
- 988 51. Chakraborty, S., et al., *Early non-neutralizing, afucosylated antibody responses are*  
989 *associated with COVID-19 severity*. Sci Transl Med, 2022. **14**(635): p. eabm7853.
- 990 52. Chakraborty, S., et al., *Proinflammatory IgG Fc structures in patients with severe COVID-*  
991 *19*. Nat Immunol, 2021. **22**(1): p. 67-73.
- 992 53. Sterlin, D., et al., *IgA dominates the early neutralizing antibody response to SARS-CoV-2*.  
993 Sci Transl Med, 2021. **13**(577).
- 994 54. Wang, Z., et al., *Enhanced SARS-CoV-2 neutralization by dimeric IgA*. Sci Transl Med, 2021.  
995 **13**(577).
- 996 55. Azzi, L., et al., *Mucosal immune response in BNT162b2 COVID-19 vaccine recipients*.  
997 EBioMedicine, 2022. **75**: p. 103788.
- 998 56. Selva, K.J., et al., *Systems serology detects functionally distinct coronavirus antibody*  
999 *features in children and elderly*. Nat Commun, 2021. **12**(1): p. 2037.
- 1000 57. Crowley, A.R., et al., *Boosting of cross-reactive antibodies to endemic coronaviruses by*  
1001 *SARS-CoV-2 infection but not vaccination with stabilized spike*. Elife, 2022. **11**.
- 1002 58. Kaplonek, P., et al., *Early cross-coronavirus reactive signatures of humoral immunity*  
1003 *against COVID-19*. Sci Immunol, 2021. **6**(64): p. eabj2901.
- 1004 59. Lin, C.Y., et al., *Pre-existing humoral immunity to human common cold coronaviruses*  
1005 *negatively impacts the protective SARS-CoV-2 antibody response*. Cell Host Microbe, 2022.  
1006 **30**(1): p. 83-96 e4.
- 1007 60. Tarke, A., et al., *Comprehensive analysis of T cell immunodominance and*  
1008 *immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases*. Cell Rep Med, 2021. **2**(2):  
1009 p. 100204.
- 1010 61. Painter, M.M., et al., *Rapid induction of antigen-specific CD4(+) T cells is associated with*  
1011 *coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination*. Immunity,  
1012 2021. **54**(9): p. 2133-2142 e3.

- 1013 62. Centers for Disease Control and Prevention. *Coronavirus Disease 2019 (COVID-19) 2021*  
1014 *Case Definition*. 2021 February 21, 2022]; Available from:  
1015 <https://ndc.services.cdc.gov/case-definitions/coronavirus-disease-2019-2021/>.
- 1016 63. Baj, J., et al., *COVID-19: Specific and Non-Specific Clinical Manifestations and Symptoms:*  
1017 *The Current State of Knowledge*. J Clin Med, 2020. **9**(6).
- 1018 64. Mallone, R., et al., *Isolation and preservation of peripheral blood mononuclear cells for*  
1019 *analysis of islet antigen-reactive T cell responses: position statement of the T-Cell*  
1020 *Workshop Committee of the Immunology of Diabetes Society*. Clinical and Experimental  
1021 Immunology, 2010. **163**(1): p. 33-49.
- 1022 65. Nilsson, C., et al., *Optimal blood mononuclear cell isolation procedures for gamma*  
1023 *interferon enzyme-linked immunospot testing of healthy Swedish and Tanzanian subjects*.  
1024 Clin Vaccine Immunol, 2008. **15**(4): p. 585-9.
- 1025 66. Hastie, K.M., et al., *Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies:*  
1026 *A global consortium study*. Science, 2021. **374**(6566): p. 472-478.
- 1027 67. Hsieh, C.L., et al., *Structure-based design of prefusion-stabilized SARS-CoV-2 spikes*.  
1028 Science, 2020. **369**(6510): p. 1501-1505.
- 1029 68. Gordon, D.E., et al., *A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug*  
1030 *Targets and Potential Drug-Repurposing*. bioRxiv, 2020.
- 1031 69. Zhang, L., et al., *SARS-CoV-2 spike-protein D614G mutation increases virion spike density*  
1032 *and infectivity*. Nat Commun, 2020. **11**(1): p. 6013.
- 1033 70. Weissman, D., et al., *D614G Spike Mutation Increases SARS CoV-2 Susceptibility to*  
1034 *Neutralization*. Cell Host Microbe, 2021. **29**(1): p. 23-31.e4.
- 1035 71. Naldini, L., et al., *Efficient transfer, integration, and sustained long-term expression of the*  
1036 *transgene in adult rat brains injected with a lentiviral vector*. Proc Natl Acad Sci U S A,  
1037 1996. **93**(21): p. 11382-8.
- 1038 72. Karsten, C.B., et al., *A versatile high-throughput assay to characterize antibody-mediated*  
1039 *neutrophil phagocytosis*. J Immunol Methods, 2019. **471**: p. 46-56.
- 1040 73. Ackerman, M.E., et al., *A robust, high-throughput assay to determine the phagocytic*  
1041 *activity of clinical antibody samples*. J Immunol Methods, 2011. **366**(1-2): p. 8-19.
- 1042 74. Fischinger, S., et al., *A high-throughput, bead-based, antigen-specific assay to assess the*  
1043 *ability of antibodies to induce complement activation*. J Immunol Methods, 2019. **473**: p.  
1044 112630.
- 1045 75. McKinnon, K.M., *Multiparameter Conventional Flow Cytometry*. Methods Mol Biol, 2018.  
1046 **1678**: p. 139-150.
- 1047 76. Acosta, J.R., et al., *Increased fat cell size: a major phenotype of subcutaneous white*  
1048 *adipose tissue in non-obese individuals with type 2 diabetes*. Diabetologia, 2016. **59**(3): p.  
1049 560-570.
- 1050 77. JMP. *Data visualization with t-SNE and UMAP*. 2020 March 14, 2022]; Available from:  
1051 [https://community.jmp.com/t5/JMP-Add-Ins/Data-visualization-with-t-SNE-and-](https://community.jmp.com/t5/JMP-Add-Ins/Data-visualization-with-t-SNE-and-UMAP/ta-p/177969)  
1052 [UMAP/ta-p/177969](https://community.jmp.com/t5/JMP-Add-Ins/Data-visualization-with-t-SNE-and-UMAP/ta-p/177969).  
1053


**Table 1. Composition of study cohort by SARS-CoV-2 infection status.**

Demographic Characteristics	Categories	SARS-CoV-2 infected		SARS-CoV-2 non-infected		Total		P value	Missing values
		n=67		n=24		n=91			
Dates of first visit		6/12/2020 - 2/27/21		6/12/2020 - 12/15/20		6/12/2020 - 2/27/21		Pearson chi square	
Households, No.		35		12		45		<b>0.0006</b>	
Subjects with follow-up visit, No. (%)		21	31.3%	1	4.2%	22	24.2%	<b>0.0269</b>	
Age, Median (Range)		31	4 - 79	34	1 - 69	31	1 - 79	<b>0.0147</b>	
	<18 years, No. (%)	7	10.4%	7	29.2%	14	15.4%	<b>0.014</b>	
	18-50 years, No. (%)	37	55.2%	15	20.8%	52	57.1%		
	51+ years, No. (%)	23	34.3%	2	8.3%	25	27.5%		
Female No. (%)		47	70.1%	12	50.0%	59	64.8%	0.0761	
Ethnicity, No. (%)	White	56	83.6%	21	87.5%	77	84.6%	0.851	
	Other	11	16.4%	3	12.5%	14	15.4%		
Body Mass Index Category, No. (%)									
	Underweight	3	4.5%	2	8.7%	5	5.6%	0.2506	2
	Healthy Weight	39	59.1%	8	34.8%	47	52.8%		
	Overweight	15	22.7%	8	34.8%	23	25.8%		
	Obese	9	13.6%	5	21.7%	14	15.7%		
Smoking, No. (%)		9	13.6%	0	0.0%	9	10.0%	0.0565	1
Has a chronic conditions, No. (%)		19	30.6%	7	31.8%	26	31.0%	0.9186	7
	Hypertension, No (%)	6	9.7%	2	9.1%	8	9.5%	0.9358	7
	Asthma, No. (%)	3	4.8%	2	9.1%	5	6.0%	0.4689	7
	High cholesterol, No. (%)	9	14.5%	1	4.5%	10	11.9%	0.2147	7
<b>COVID specific details</b>									
Reported symptoms with illness, No. (%)		58	86.6%	14	58.3%	72	79.1%	<b>0.0035</b>	
visited the ER for suspected illness, No. (%)		9	13.4%	1	4.2%	10	11.0%	0.213	
tested SARS-CoV-2+ (PCR self), No. (%)		42	62.7%	0	0.0%	42	46.2%	<b>&lt;0.0001</b>	
tested SARS-CoV-2+ (PCR household), No. (%)		53	79.1%	0	0.0%	53	58.2%	<b>&lt;0.0001</b>	
Plasma viral RNA detected, No. (%)		11	16%	0	0%	0	12%	<b>0.0343</b>	
Serostatus, No. (%)	anti-S positive	54	80.6%	0	0.0%	54	59.3%	<b>&lt;0.0001</b>	
	anti-S indeterminant	6	9.0%	3	12.5%	9	9.9%		
	anti-S negative	7	10.4%	21	87.5%	28	30.8%		
	anti-N positive	32	47.8%	0	0.0%	32	35.2%	<b>&lt;0.0001</b>	
	anti-N indeterminant	28	41.8%	3	12.5%	31	34.1%		
	anti-N negative	7	10.4%	21	87.5%	28	30.8%		
met COVID-19 case definition		51	76%	0	0%	51	56%	<b>&lt;0.0001</b>	
mean days from possible exposure (range)		93	(23-252)	133	(10-289)	104	(10-289)	0.1119	


**Figure 1**




A.




B.




C.




D.




E.




F.




**A.**







**B.**




**C.**

















A.




B.




A.




B.





C.






D.
















**D. all post-vaccination responses**




**E. >90 days post-vaccination responses**



**F.**



## <90 days post-vaccination responses



**B.** correlations to post-vaccination neutralization titers (all samples or >90 days)

